CSFRefresh

United States
Melba, Idaho, United States

Company profile

CSFRefresh company profile

CSFRefresh develops a safe and effective treatment for Alzheimer’s disease by improving the removal of AD toxins from the brain. It is developing a novel biomedical device, a patent-pending “smart”, self-regulating cerebrospinal fluid (CSF) shunt capable of improving the CSF circulation. Increasing the CSF turnover rate, the rate at which the CSF volume is replaced each day will clear toxic metabolites from the brain, e.g, amyloid-beta peptide (Aβ) and phospho-tau (pTau) that cause AD. Normal CSF turnover is 4-5 volumes/day. In AD and NPH it is reduced to once/day.

Business identity

Operating status
Active
Company type
For Profit

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
2
Total equity funding
$70,000
Last funding
Undisclosed / $70,000 / 2022-07-15
Last equity funding
Undisclosed / $70,000
Articles
1

Founders and investors

No public relation records are available.